TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ValiRx plc ( (GB:VAL) ) has issued an announcement.
ValiRx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £152,000 through the issuance of new ordinary shares. Combined with previous fundraising efforts, the company has secured a total of £902,000. The new shares are expected to commence trading on AIM by 21 November 2025, subject to the approval of Fundraising Resolutions at the General Meeting. This fundraising effort is anticipated to bolster ValiRx’s financial position and support its strategic initiatives in the life sciences sector.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
Spark’s Take on GB:VAL Stock
According to Spark, TipRanks’ AI Analyst, GB:VAL is a Underperform.
ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, marked by significant losses and reliance on external financing. The technical analysis indicates bearish trends, with the stock being oversold. Valuation metrics are unfavorable due to negative earnings and lack of dividends. These factors collectively suggest a high-risk investment profile.
To see Spark’s full report on GB:VAL stock, click here.
More about ValiRx plc
ValiRx Plc is a life sciences company specializing in early-stage cancer therapeutics and women’s health.
Average Trading Volume: 2,804,398
Technical Sentiment Signal: Sell
Current Market Cap: £935.9K
See more data about VAL stock on TipRanks’ Stock Analysis page.